Animal model considerations for chordoma research: reproducing the tumor microenvironment in vivo with humanized mice DOI Creative Commons
Beatrice Campilan,

Christian Schroeder,

Emilija Sagaityte

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: March 13, 2024

Animal models have been commonly used in immunotherapy research to study the cell response external agents and assess effectiveness safety of new therapies. Over past few decades, immunocompromised (also called immunodeficient) mice allowed researchers grow human tumor cells without impact host’s immune system. However, while this model is very valuable understand biology underlying mechanism immunotherapy, results may not always directly translate humans. The microenvironment has significant implications for engraftment, growth, invasion, etc., system plays a critical role shaping microenvironment. Human immunocompetent mice, also named humanized are engineered that possess functional cells. This vivo can be effectively effect implanted tumor. Moreover, mimic treatment. section an overview current understanding different could utilized chordoma.

Language: Английский

Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancer DOI Creative Commons
Young-Ju Kwon, Dong Young Kim,

Uk-Il Kim

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116842 - 116842

Published: Feb. 1, 2025

Language: Английский

Citations

0
Intratumoral heterogeneity and drug resistance in cancer DOI Creative Commons

Yue-Chun Fu,

Shao-Bo Liang,

Min Luo

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 18, 2025

Intratumoral heterogeneity is the main cause of tumor treatment failure, varying across disease sites (spatial heterogeneity) and polyclonal properties tumors that evolve over time (temporal heterogeneity). As our understanding intratumoral heterogeneity, formation which mainly related to genomic instability, epigenetic modifications, plastic gene expression, different microenvironments, plays a substantial role in drug-resistant as far metastasis recurrence. Understanding it becomes clear single therapeutic agent or regimen may only be effective for subsets cells with certain features, but not others. This necessitates shift from current, unchanging approach one tailored against killing patterns cancer clones. In this review, we discuss recent evidence concerning global perturbations associations specific lung cancer, underlying mechanisms potentially leading formation, how drives drug resistance. Our findings highlight most up-to-date progress its mediating resistance, could support development future strategies.

Language: Английский

Citations

0
Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics DOI
Fares Saeed H. Al-Mansour, Hassan H. Almasoudi, Ali Albarrati

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Language: Английский

Citations

0
A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients† DOI Creative Commons
Paola Defilippi,

Francesca Nigrelli,

Pietro Arina

et al.

The Journal of Pathology, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

Abstract Breast cancer includes a group of neoplasms originating from mammary gland epithelial cells caused by variety genetic alterations, with different responses to treatments and outcomes. In clinical practice, estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2) expression guides the distinction between luminal A (ER + , PR HER2 − ), B +/− triple‐negative each distinct biological behavior therapeutic implications. Approximately 11% breast cancers are diagnosed in young premenopausal women aged 20–49 years. Patient‐derived xenografts (PDXs) offer powerful solution integrate personalized medicine novel agents. Dr Belletti's recently developed PDX biobank composed 26 lines highly enriched patients. The bank faithfully recapitulates characteristics original tumors. major focus their research was exploit these PDXs assess resistance CDK4/6 inhibitors (CDK4/6i), which critical managing advanced cancers. Their effort addresses significant gap existing models, limited for patient subgroups, thereby enabling deeper insights into tumor biology understudied populations. © 2025 Author(s). Journal Pathology published John Wiley & Sons Ltd on behalf Pathological Society Great Britain Ireland.

Language: Английский

Citations

0
Eco-Friendly Nanotherapeutics: Metallic Nanoparticles for Targeting Breast Cancer DOI

Darakhshan Javaid,

Shahid Yousuf Ganie,

Syed Sanober Qadri

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177603 - 177603

Published: April 1, 2025

Language: Английский

Citations

0
Small molecule therapeutics for receptor-mediated targeting through liposomes in breast cancer treatment: A comprehensive review DOI
Rashmi Ghosh,

Manish Kumar,

Sourabh Kumar

et al.

Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 108442 - 108442

Published: April 1, 2025

Language: Английский

Citations

0
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care DOI
Emna El Gazzah, Scott Parker, Mariaelena Pierobon

et al.

Expert Review of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Breast cancer remains a major global health challenge. While advances in precision oncology have contributed to improvements patient outcomes and provided deeper understanding of the biological mechanisms that drive disease, historically, research patients' allocation treatment heavily relied on single-omic approaches, analyzing individual molecular dimensions such as genomics, transcriptomics, or proteomics. these deep insights into breast biology, they often fail offer complete disease's complex landscape. In this review, authors explore recent advancements multi-omic realm using clinical data show how integration can more holistic alterations their functional consequences underlying cancer. The overall developments AI are expected complement diagnostics through potentially refining prognostic models, selection. Overcoming challenges cost, complexity, lack standardization is crucial for unlocking full potential multi-omics care enable advancement personalized treatments improve outcomes.

Language: Английский

Citations

0
Application of DCE-MRI radiomics and heterogeneity analysis in predicting luminal and non-luminal subtypes of breast cancer DOI Creative Commons
Ming Yao,

Dingli Ye,

Yuchong Wang

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 16, 2025

The aim of this study was to explore the application value dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) radiomics and heterogeneity analysis in differentiation molecular subtypes luminal non-luminal breast cancer. In retrospective study, 388 female cancer patients (48.37 ± 9.41 years) with (n = 190) 198) who received surgical treatment at Jilin Cancer Hospital were recruited from January 2019 June 2023. All underwent MRI scan DCE before surgery. then divided into a training set 272) validation 116) 7:3 ratio. three-dimensional texture feature parameters lesion areas extracted. Four tumor parameters, including type I curve proportion, II III proportion values calculated normalized. Five machine learning (ML) models, logistic regression, naive Bayes algorithm (NB), k-nearest neighbor (KNN), decision tree (DT) extreme gradient boosting (XGBoost) model used process data further validated. best ML selected according performance set. subtype lesions, index significantly lower than corresponding lesions both Eight features together four heterogeneity-related significant differences between groups retained as signatures for constructing prediction model. regression achieved highest area under (0.93), accuracy (86.94%), sensitivity (87.55%) specificity (86.25%). based on DCE-MRI exhibit good discriminating demonstrates predictive among various models.

Language: Английский

Citations

0
Tumors and their microenvironments: Learning from pediatric brain pathologies DOI Creative Commons
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: 1880(3), P. 189328 - 189328

Published: April 18, 2025

Language: Английский

Citations

0
Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues DOI
Ana Leda F. Longhini, Inés Fernández-Maestre, Margaret C. Kennedy

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 27, 2024

Introduction In vivo studies of cancer biology and assessment therapeutic efficacy are critical to advancing research ultimately improving patient outcomes. Murine models have proven be an invaluable tool in pre-clinical studies. this context, multi-parameter flow cytometry is a powerful method for elucidating the profile immune cells within tumor microenvironment and/or play role hematological diseases. However, designing appropriate panel comprehensively increasing diversity across different murine tissues can extremely challenging. Methods To address issue, we designed with 13 fixed markers that define major populations –referred as backbone panel– profiled but option incorporate up seven additional fluorochromes, including any marker specific study question. Results This maintains its resolution spectral cytometers organs, both hematopoietic non-hematopoietic, well tumors complex microenvironments. Discussion Having robust easily customized pre-validated drop-in fluorochromes saves time resources brings consistency standardization, making it versatile solution immuno-oncology researchers. addition, approach presented here serve guide develop similar types customizable panels questions requiring high-parameter panels.

Language: Английский

Citations

3